Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137364 | 0.85 | GAA (0.43) | HSD11B1ALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL4136419 | 0.82 | HSD11B1 (0.56) | HSD11B1ALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL4130981 | 0.81 | HSD11B1 (0.57) | HSD11B1ALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL4141023 | 0.80 | HSD11B1 (0.56) | HSD11B1ALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL4143969 | 0.80 | HSD11B1 (0.55) | HSD11B1ALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL4137544 | 0.79 | HSD11B1 (0.54) | HSD11B1ALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL4132068 | 0.76 | HSD11B1 (0.49) | HSD11B1ALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL4715877 | 0.68 | KMT2A (0.50) | HSD11B1ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4145485 | 0.68 | KMT2A (0.71) | ALDH1A1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL4145482 | 0.68 | KMT2A (0.71) | ALDH1A1KMT2AMEN1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156644-A1 | Use of thiazole derivatives and analogues in the treatment of cancer | BETAGENON AB (SE) | 2009-06-18 | — | — | US | disclosed |
| US-20090136472-A1 | Use of thiazole derivatives and analogues in disorders caused by free fatty acids | BETAGENON AB (SE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008090327-A1 | NEW COMBINATION FOR USE IN THE TREATMENT OF CANCER | BETAGENON AB (SE) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008065409-A2 | COMBINATION FOR USE IN THE TREATMENT OF CANCER, COMPRISING TAMOXIFEN OR AN AROMATASE INHIBITOR | BETAGENON AB (SE) | 2008-06-05 | — | — | WO | disclosed |
| EP-1906955-A2 | USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN THE TREATMENT OF CANCER | Betagenon AB (SE) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007010273-A2 | USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN THE TREATMENT OF CANCER | BETAGENON AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156644-A1 | Use of thiazole derivatives and analogues in the treatment of cancer | TBXA2R, TSHR, FOLR1 | HSD11B1 1506/4885ALDH1A1 312/4885KMT2A 1742/4885 |
| US-20090136472-A1 | Use of thiazole derivatives and analogues in disorders caused by free fatty acids | FFAR2, FFAR1, FFAR4 | HSD11B1 218/4885ALDH1A1 707/4885KMT2A 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.